All In Biotech

Drug Trial Radar · NCT07462780

A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy Participants

A Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase I Study to Evaluate the Safety, Tolerability, PK and PD Characteristics of CMS-D017 Following Single and Multiple Administrations in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

88

Planned (sponsor's estimate)

Start

Mar 5, 2026

Primary completion

Nov 2026

Study completion Dec 2026

Sponsor

Sponsor type
Industry
First posted
Mar 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a first-in-human (FIH) trial of CMS-D017 conducted in healthy Chinese adult participants, consisting of two parts: Part 1-a single ascending dose (SAD) study (referred to as Part 1 SAD), and Part 2-a multiple ascending dose (MAD) study (referred to as Part 2 MAD). The study aims to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) characteristics of CMS-D017 capsules following single and multiple oral administrations in healthy Chinese adult participants. Both parts of the study are designed as randomized, double-blind, placebo-controlled, sequential cohort trials. Part 1 SAD plans to include 6 dose cohorts, with 8 participants per cohort (6 receiving CMS-D017 and 2 receiving placebo), for a total of 48 participants. Part 2 MAD plans to include 4 dose cohorts, with 10 participants per cohort (8 receiving CMS-D017 and 2 receiving placebo), for a total of 40 participants.

Conditions

  • Paroxysmal Nocturnal Hemoglobinuria, PNH
  • Complement-mediated Kidney Disease

Interventions

  • CMS-D017 CapsuleDrug

    healthy participant

  • CMS-D017 Placebo CapsuleDrug

    healthy participant

  • CMS-D017 CapsuleDrug

    healthy subject

  • CMS-D017 Placebo CapsuleDrug

    healthy subject

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of CMS-D017 -Adverse eventsTime frame: Up to 23 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Third Hospital

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.